Isabel Neckermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabel Neckermann has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Abiha Abdullah
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 shared publicationsAmaan Rahman
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 shared publicationsCharbel Elias
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 shared publicationsChristopher Kaltenmeier
Department of Surgery, Georgetown University, Washington D.C., USA
2 shared publicationsEishan Ashwat
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 shared publicationsHao Liu
J.C. Walter Jr. Transplant Center and Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Society of Hematology in Blood Advances
An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy
Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.
- 2 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessAn Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy
Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.
- Open Access
- 1 March 2026
- Vol. 40 (3) , e70488
Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit-Based Model.
Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002-2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi-visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development (n = 15,282) and validation (n = 15,283) cohorts. The primary outcome was 5-year LT survival benefit, defined as the difference in survival with and without LT. C-MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC-Liver Transplant Survival Benefit model was defined as HCC-LTSB = 0.65 × (C-MELD 145 3.0 - 6) + 1.99 × (TBS - 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93-0.94; R2 = 0.87; C-index = 0.91). The HCC-LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.
- 1 March 2026
- Vol. 40 (3) , e70488
Open AccessOptimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit-Based Model.
Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002-2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi-visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development (n = 15,282) and validation (n = 15,283) cohorts. The primary outcome was 5-year LT survival benefit, defined as the difference in survival with and without LT. C-MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC-Liver Transplant Survival Benefit model was defined as HCC-LTSB = 0.65 × (C-MELD 145 3.0 - 6) + 1.99 × (TBS - 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93-0.94; R2 = 0.87; C-index = 0.91). The HCC-LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.
- Open Access
- 25 February 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model
Introduction: Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Methods: Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002–2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi‐visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development ( n = 15,282) and validation ( n = 15,283) cohorts. The primary outcome was 5‐year LT survival benefit, defined as the difference in survival with and without LT. Results: C‐MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC‐Liver Transplant Survival Benefit model was defined as HCC‐LTSB = 0.65 × (C‐MELD 145 3.0 − 6) + 1.99 × (TBS − 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93–0.94; R 2 = 0.87; C‐index = 0.91). Conclusion: The HCC‐LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.
- 25 February 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Open AccessOptimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model
Introduction: Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Methods: Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002–2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi‐visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development ( n = 15,282) and validation ( n = 15,283) cohorts. The primary outcome was 5‐year LT survival benefit, defined as the difference in survival with and without LT. Results: C‐MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC‐Liver Transplant Survival Benefit model was defined as HCC‐LTSB = 0.65 × (C‐MELD 145 3.0 − 6) + 1.99 × (TBS − 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93–0.94; R 2 = 0.87; C‐index = 0.91). Conclusion: The HCC‐LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.